Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice

J Zeng, X Xie, XL Feng, L Xu, JB Han, D Yu, QC Zou… - …, 2022 - thelancet.com
Summary Background The Coronavirus Disease 2019 (COVID-19) pandemic has been a
great threat to global public health since 2020. Although the advance on vaccine …

Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19

B Pitt, AM Tate, D Gluck, RS Rosenson… - European Heart …, 2022 - academic.oup.com
Abstract Coronavirus disease 2019 (COVID-19) is characterized by striking dysregulation of
the immune system, with evidence of hyperinflammation, an impaired induction of …

Pathophysiological mechanisms of thrombosis in acute and long COVID-19

H Jing, X Wu, M Xiang, L Liu, VA Novakovic… - Frontiers in …, 2022 - frontiersin.org
COVID-19 patients have a high incidence of thrombosis, and thromboembolic complications
are associated with severe COVID-19 and high mortality. COVID-19 disease is associated …

Severe COVID-19: NLRP3 inflammasome dysregulated

DF Van den Berg, AA Te Velde - Frontiers in immunology, 2020 - frontiersin.org
SARS-CoV-2 might directly activate NLRP3 inflammasome resulting in an endogenous
adjuvant activity necessary to mount a proper adaptive immune response against the virus …

SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation

P Pan, M Shen, Z Yu, W Ge, K Chen, M Tian… - Nature …, 2021 - nature.com
Excessive inflammatory responses induced upon SARS-CoV-2 infection are associated with
severe symptoms of COVID-19. Inflammasomes activated in response to SARS-CoV-2 …

Thromboplasminflammation in COVID-19 coagulopathy: three viewpoints for diagnostic and therapeutic strategies

S Gando, T Wada - Frontiers in Immunology, 2021 - frontiersin.org
Thromboplasminflammation in coronavirus disease 2019 (COVID-19) coagulopathy consists
of angiotensin II (Ang II)-induced coagulopathy, activated factor XII (FXIIa)-and kallikrein …

Innate immunology in COVID-19—a living review. Part II: dysregulated inflammation drives immunopathology

PRS Rodrigues, A Alrubayyi, E Pring… - Oxford open …, 2020 - academic.oup.com
The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a global health crisis and will …

Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology

M Wang, F Yu, W Chang, Y Zhang, L Zhang… - Frontiers in …, 2023 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a contagious respiratory
virus that is the cause of the coronavirus disease 2019 (COVID-19) pandemic which has …

Preventing the development of severe COVID-19 by modifying immunothrombosis

G Morris, CC Bortolasci, BK Puri, L Olive, W Marx… - Life sciences, 2021 - Elsevier
Background COVID-19-associated acute respiratory distress syndrome (ARDS) is
associated with significant morbidity and high levels of mortality. This paper describes the …

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

A Bonaventura, A Vecchié, L Dagna… - Nature Reviews …, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe …